The American Journal of Managed Care

Other Clinical Considerations in Demodex Blepharitis Treatment

This is a video synopsis/summary of an Insights involving Eric D. Donnenfeld, MD. The best way ophthalmologists and optometrists can work with payers to ensure access to the important new ...
The American Journal of Managed Care

Exploring Demodex Blepharitis From a Clinical Perspective

AJMC®: Does the prevalence of Demodex blepharitis found by Trattler and colleagues 1 match what you see in clinical practice? BRUJIC: The prevalence of Demodex blepharitis is interesting. Prior to ...
MM&M

Tarsus Pharmaceuticals throws a Mite Party to combat demodex blepharitis

Welcome to the Mite Party. In its latest effort to raise awareness about demodex blepharitis, an eye condition that affects 25 million Americans, Tarsus Pharmaceuticals is throwing a party — a Mite ...
FOX8 Cleveland

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available ...
Nature

Demodex Mite Infestation and Associated Conditions

The Demodex mite is a ubiquitous microscopic ectoparasite that colonises the pilosebaceous units on human skin, notably the eyelids, where it may contribute to conditions such as blepharitis and ...
WKRN-TV

Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug ...

IRVINE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...